Search

[Podcast Recap] How Biosimilars Are Reshaping Employer Pharmacy Costs

By Maddison Bezdicek — Vice President, Strategic Vendor Services October 06th, 2026

In Episode 23 of Captivating Health Insights, host Maddison Bezdicek sat down with Brian Shonat and Giorgio Vescera of Navion to explore how biosimilars are reshaping the pharmacy benefit landscape and what employers should consider when evaluating their pharmacy benefit manager (PBM) strategy.

Biosimilars are highly similar alternatives to existing biologic medications, with no clinically meaningful differences in safety or effectiveness, and can offer a lower-cost option for high-cost specialty drugs such as Humira and Stelara. As these products gain traction, Shonat and Vescera explained how lower upfront drug costs, changing rebates, and different PBM approaches are creating a new equation for employers evaluating pharmacy costs.

The conversation explored how rebates, formulary design — the list of prescription drugs covered by a health plan and how they are categorized or preferred — member cost sharing, contract language, and utilization can influence an employer’s true net cost and why understanding these factors is increasingly important as biosimilar adoption grows.

Core Themes from Episode 23: Biosimilars and the New PBM Math

Biosimilars Are Changing the Pharmacy Cost Equation

Vescera explained that biosimilars offer clinically similar alternatives to their originator biologic products, often at a significantly lower upfront cost. As biosimilars for drugs such as Humira and Stelara gain adoption, employers may see more savings when a prescription is filled rather than waiting months for manufacturer rebates. This shift is changing how employers should evaluate the overall economics of their pharmacy benefits.

Lower Rebates Do Not Necessarily Mean Higher Costs

Employers have traditionally looked to rebate guarantees when evaluating PBM contracts. But as utilization shifts from highly rebated brand-name drugs to lower-cost biosimilars, those rebate amounts may decline. Vescera emphasized that employers should consider both sides of the equation: lower rebates may accompany lower upfront drug costs. Understanding the true net cost requires evaluating how those pieces work together rather than focusing on rebates alone.

Formulary Design Can Drive Biosimilar Adoption

The discussion highlighted the role formulary design plays in determining whether members transition to biosimilars. Some formularies may prefer a biosimilar, while others may offer both the originator drug and biosimilar at the same tier. Shonat and Vescera explained that PBMs are taking different approaches, making it important for employers to understand which products are preferred and how those decisions align with their plan’s utilization.

Member Cost-Sharing Influences Behavior

Shonat emphasized that plan design can also affect whether members choose a biosimilar. If a familiar brand-name drug and a biosimilar have the same out-of-pocket cost, members may have little financial incentive to switch, even when the biosimilar costs the health plan less. Differences in member cost-sharing can help influence those decisions, while education can help members understand their options.

Contract Language Matters

The conversation also explored rebate credit language, which has become increasingly important as lower-cost biosimilars enter the market. Depending on the PBM contract, savings associated with a lower-cost product may affect the rebates ultimately paid to the plan. Because PBMs may calculate these credits differently, Vescera encouraged employers to look beyond headline rebate guarantees and understand how contract language affects the overall economics.

Utilization Should Guide the Strategy

A biosimilar-focused strategy may not produce the same results for every employer. Shonat and Vescera explained that an organization’s existing utilization can significantly influence which approach makes the most financial sense. For smaller employers, the addition or departure of a single high-cost claimant can meaningfully change plan performance. Regularly reviewing utilization can help employers determine whether their current PBM and formulary strategy continues to align with their needs.

Employers Should Keep Asking Questions

As the PBM landscape becomes more complex, both guests emphasized the importance of asking questions. Employers do not need to become pharmacy experts, but they should understand their PBM’s biosimilar strategy, formulary options, rebate provisions, and potential impact on their plan. Working with brokers and pharmacy consultants to evaluate these details can help employers determine whether their current approach is producing the best results for their population.

Want the Full Story? Listen to Episode 23

This recap captures only part of the conversation about biosimilars and the changing PBM landscape. Listen to Episode 23 of Captivating Health Insights to hear a deeper discussion of how biosimilars are reshaping pharmacy costs, rebates, formularies, and PBM contracts — and what employers should consider as they evaluate their strategy.

As biosimilar adoption continues to grow, understanding the details behind the numbers can help employers evaluate their options and make informed decisions based on their plan’s utilization, contract terms, and overall goals.

Listen and subscribe on your favorite platforms, including YouTube, Apple, Spotify, Amazon Music, Pandora, and Pocket Casts, to learn how employers can better understand the evolving biosimilar landscape and evaluate the true cost of their pharmacy benefit strategy.

Share this article